Tirofiban

Generic Name: Tirofiban

Brand Names: Aggrastat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₆N_₂O_₅S

CAS Number: 144494-65-5

Unique Ingredient Identifier: GGX234SI5H

Background: Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

Indication: For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

Phase 3

Recruiting

Conditions: Symptomatic Intracranial Artery Stenosis
Ischemic Stroke, Acute
TIA

Interventions: Drug: Placebo
Drug: Tirofiban

First Posted Date: 2024-03-20

Last Posted Date: 2024-07-12

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 4674

Registration Number: NCT06319846

Locations: 🇨🇳
The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳
People's Hospital of Qihe County, Dezhou, Shandong, China
🇨🇳
Liaocheng People's Hospital（Liaocheng Brain Hospital）, Liaocheng, Shandong, China

and more 2 locations

Tirofiban After Successful MT Recanalization in AIS

Phase 2

Recruiting

Conditions: Acute Ischemic Stroke
Vessel Occlusion

Interventions: Drug: Tirofiban
Drug: Saline placebo

First Posted Date: 2024-02-20

Last Posted Date: 2024-05-28

Lead Sponsor: Xiang Luo

Target Recruit Count: 1360

Registration Number: NCT06265051

Locations: 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Phase 2

Recruiting

Conditions: Unruptured Intracranial Aneurysm
Stent-assisted Coiling
Flow Diverter
Thromboembolic Events

Interventions: Drug: Tirofiban
Drug: aspirin, clopidogrel

First Posted Date: 2024-02-02

Last Posted Date: 2024-03-06

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 190

Registration Number: NCT06238115

Locations: 🇨🇳
Beijing Tiantan Hospital, Beijing, China

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Not Applicable

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Tirofiban simulant
Drug: Tirofiban

First Posted Date: 2023-09-21

Last Posted Date: 2024-05-23

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 1084

Registration Number: NCT06045156

Locations: 🇨🇳
The first hospital of Jilin University, Chang chun, Jilin, China

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Phase 3

Recruiting

Conditions: Branch Atheromatous Disease

Interventions: Drug: Aspirin tablet
Drug: Tirofiban
Drug: Clopidogrel tablet

First Posted Date: 2023-09-14

Last Posted Date: 2024-08-27

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 516

Registration Number: NCT06037889

Locations: 🇨🇳
Jun Ni, Beijing, Beijing, China
🇨🇳
Beijing Shunyi Hospital, Beijing, Beijing, China
🇨🇳
The second hospital of Baoding, Baoding, Hebei, China

and more 18 locations

Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban

Phase 4

Recruiting

Conditions: Intracranial Aneurysm

Interventions: Drug: normal saline
Drug: Tirofiban

First Posted Date: 2023-05-03

Last Posted Date: 2023-05-03

Lead Sponsor: Lu Hua

Target Recruit Count: 70

Registration Number: NCT05841147

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, China

Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke

Phase 2

Recruiting

Conditions: Stroke, Acute Ischemic

Interventions: Drug: Tirofiban
Drug: Alteplase

First Posted Date: 2023-02-15

Last Posted Date: 2024-01-03

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 800

Registration Number: NCT05728333

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion

Phase 4

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Tirofiban
Drug: Acetylsalicylic acid

First Posted Date: 2022-02-07

Last Posted Date: 2024-03-07

Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Target Recruit Count: 240

Registration Number: NCT05225961

Locations: 🇪🇸
Virgen del Rocío Hospital, Seville, Spain
🇪🇸
Ramón y Cajal Hospital, Madrid, Spain
🇪🇸
Complejo Hospital Universitario de Badajoz, Badajoz, Spain

and more 10 locations

Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.

Phase 4

Conditions: ST Elevation Myocardial Infarction

Interventions: Drug: Normal saline
Drug: Tirofiban

First Posted Date: 2019-01-09

Last Posted Date: 2020-01-22

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 500

Registration Number: NCT03797729

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

Tirofiban for Patients Treated With Alteplase

Phase 2

Terminated

Conditions: Ischemic Stroke

Interventions: Drug: Alteplase
Drug: Tirofiban

First Posted Date: 2017-11-29

Last Posted Date: 2020-09-09

Lead Sponsor: Capital Medical University

Target Recruit Count: 30

Registration Number: NCT03357133

Locations: 🇨🇳
The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China
🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Luzhou People's Hospital, Luzhou, Sichuan, China

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy